NAMPT and posterior cortical atrophy: Using FK866 (a nicotinamide phosphoribosyltransferase/NAMPT inhibitor) as a proof-of-concept secDrug, we established a novel, universally applicable, preclinical drug development pipeline that incorporates bulk-tumor and single-cell RNA sequencing, microfluidics, as well as in vitro (cell line models representing clinically advanced PCa), and patient-based validation to introduce secondary drug choices to potentially circumvent subclonal aggressiveness, drug resistance, and stemness for the management of lethal subtypes of PCa.